In a recent congressional trade report, Congresswoman Debbie Wasserman Schultz, representing Florida's 25th district, has engaged in several stock transactions.
The report reveals that Schultz purchased shares in Baxter International Inc. (NYSE:{{7951|BABAX), a global medical products company. The transaction, dated November 18, 2024, was valued between $1,001 and $15,000. This acquisition expands Schultz's investment portfolio in the healthcare sector.
On the same day, Schultz also sold her stake in New Gold Inc. (AMEX:NYSE:NGD), a multinational mining company. The sale was worth between $1,001 and $15,000. It's unclear why Schultz decided to divest from the mining sector at this time.
Earlier in the month, on October 23, 2024, Schultz made two more purchases. She acquired stocks in Patterson-UTI (NASDAQ:PTEN) Energy, Inc. (NASDAQ:PTEN), an oil drilling company, and ViaSat , Inc. (NASDAQ:VSAT), a satellite and wireless communications company. Both transactions were valued between $1,001 and $15,000.
These transactions provide insight into the investment strategies of Congresswoman Schultz. However, it's important to note that these trades do not necessarily reflect her political views or policy intentions.
InvestingPro Insights
Congresswoman Debbie Wasserman Schultz's recent investment in Baxter International Inc. (NYSE:BAX) comes at an interesting time for the company. According to InvestingPro data, Baxter's stock is currently trading near its 52-week low, with a price at 74.91% of its 52-week high. This could suggest that Schultz sees potential value in the company at its current price point.
InvestingPro Tips highlight that Baxter has maintained dividend payments for 54 consecutive years, showcasing its financial stability. This long-standing commitment to shareholder returns might have been an attractive factor for Schultz's investment decision. Additionally, the company is expected to remain profitable this year, according to analyst predictions.
However, it's worth noting that 9 analysts have revised their earnings downwards for the upcoming period, which could indicate some near-term challenges for the company. Baxter's P/E ratio stands at 156.04, suggesting it's trading at a high earnings multiple compared to its peers.
For investors interested in a deeper analysis of Baxter International, InvestingPro offers 11 additional tips that could provide valuable insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.